kidney cancer drug

A drug that has been shown to slow the growth of renal cell carcinoma may have moved a step closer to becoming a viable addition to the arsenal of patients fighting malignant mesothelioma. Temsirolimus is a kinase inhibitor that appears to work against mesothelioma, in part, by blocking the action of a protein that tells cancer cells to replicate. In laboratory tests on isolated tumor cells, temsirolimus effectively blocked the gene pathway known as mammalian target of rapamycin (mTOR) that is responsible for signaling the growth and division of all types of mesothelioma. Now, a new study conducted by scientists in Greece and the UK suggests that the compound may do the same thing in living patients. The doctors induced…